Posted by jrbecker76 on February 3, 2009, at 17:09:30
In reply to flibanserin pimavanserin eplivanserin volinanserin, posted by iforgotmypassword on February 3, 2009, at 7:31:57
> which has the best chance of being released? which may be the soonest? any sort of time-frames indicated lately? does anyone know where this drugs are in terms of approval in the united states and/or canada, or anywhere?
>
> flibanserin seems very interesting as it doesn't seem to be an SRI (unlike the other 5-HT2a antagonist nefazodone), and could in an important way be opposite in effect as a 5-HT1a (partial?) agonist. i am concerned with alieviating extrapyramidal symptoms, increasingly unreliable mobility, and broad mental deadening (apathy, avolition, amotivation, loss of creativity, loss of real appreciation of anything artistically, loss of meaningful spontaneous fluency) that may be a consequence of excessive serotonergic input that didn't remedy after taking SSRIs.
>
> pimavanserin may also be very interesting, especially while also being an M1 agonist in addition to it's 5-HT2/D2,3 effects, but they will have to elaborate on how it operates as a D2,3 partial agonist, if it stays on the agonist side of things under all situations particularly in the striatum. (a problem with aripiprazole) pimavanserin to my knowledge has no 5-HT1a affinity, but i may be wrong, it would be very interesting if it is also a meaningful 5-HT1A agonist/partial-agonist.Ectris (Flibanserin) - as the previous poster mentioned, this is now being tested for sexual dysfunction in woman. It has plans to be submitted to the FDA in '10. Given the indication that it is being marketed for, it will probably be difficult to have this used off-label and have insurers pay for it. Secondary to that, I'm not sure insurers will elect to pay for a full 30-day supply (not unlike ED drugs for men).
Pimavanserin (ACP 103)- its interactions with dopamine and acetylcholine are minimal. It is basically considered a strong 5-HT2a inverse agonist. Currently, the lead indication is parkinson's-induced psychosis. It is in Phase IIIa and still needs to sponsor another major trial and seek out a pharm partner, so it probably won't be submitted to the FDA until at least 2011.
Eplivanserin and Volinanserin. Eplivanserin has already been submitted to the FDA late last year, however, I wouldn't look for it to be approved and on the market until at least early 2010.
JB
poster:jrbecker76
thread:877770
URL: http://www.dr-bob.org/babble/20090203/msgs/877849.html